secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2025-02-05T23:59:59+00:00
Accession:  0001104659-25-009384
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Collegium expands board, appoints Nancy Lurker as new director
--------------------------------------------------------------

- Board expanded from 8 to 9 directors; Nancy Lurker appointed effective Feb 4, 2025.
- Lurker, 67, former CEO of EyePoint Pharmaceuticals, currently vice chair of EyePoint board.
- She will receive annual cash retainer of $50,000 (prorated) and equity award of $412,500 in RSUs vesting over 1 year.
- Board determined Lurker is independent under Nasdaq rules; no related party transactions.
- She also serves on boards of Alkermes (ALKS), Altasciences, and National Sanitation Foundation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000110465925009384/0001104659-25-009384-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000110465925009384/tm255440d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-009384

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer